Read + Share
Rea D, Mauro MJ, Boquimpani C, Minami Y, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs
bosutinib in CML after 2 or more prior TKIs. Blood 2021;138:2031-2041.
PMID: 34407542
|
 |
|
Rea D, Mauro MJ, Boquimpani C, Minami Y, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs
bosutinib in CML after 2 or more prior TKIs. Blood 2021;138:2031-2041.
PMID: 34407542
|
|
|
|